First-to-market, fast multiplex real-time RT-PCR Kits Available from QIAGEN
One of many new products available for gene expression analysis and siRNA validation enabling reliable, sensitive, reproducible results
Venlo, The Netherlands - May 12, 2009 - The real-time RT-PCR market is characterized by the need to reduce reaction volumes while combining the control and target in one tube without compromising overall performance. Researchers are now able to procure solutions to help meet these goals in the labs. QIAGEN today launches QuantiFast® Multiplex RT-PCR Kits and Rotor-Gene® Multiplex RT-PCR Kits. The QuantiFast Kits are the first-to-market in fast multiplex real-time RT-PCR without requiring optimization on both standard and fast real-time cyclers for one-step applications. The Rotor-Gene Kit allows detection of up to four targets per tube and includes optimized protocols for highly precise results on the Rotor-Gene Q. With the introduction of these kits, QIAGEN becomes the first vendor to be able to offer customers a complete portfolio for 1-step and 2-step RT-PCR.
Gene expression and function (GEF) analysis plays an important role in areas such as cancer research, enabling biomarker identification, target validation, and drug development. Of importance to researchers is the ability to achieve accurate real-time PCR with minimum time and effort. These innovative fast real-time PCR technologies provide speed and accuracy not only on fast cyclers, but also on standard cyclers. For applications such as gene silencing by siRNAs, the entire real-time PCR workflow can be streamlined by eliminating the need for RNA purification and allowing analysis of multiple targets in one tube.
"QIAGEN offers the broadest portfolio of products on the market for manual and automated gene expression and function analysis," said Dr. Annette Tietze, Senior Global Product Manager, qPCR products. "Our customers who perform real-time PCR and gene silencing are able to achieve success in all steps of their experiments without the need for optimization. Our newest products are helping customers standardize experiments, save time and cost due to ease of use, and provide reliable automation of higher throughput experiments."
Another key component in the gene expression workflow is the new TissueLyser LT. This instrument uses bead mill technology to break-up tissue and provide fast access to DNA, RNA, and proteins. This small, easy-to-operate bead mill can process up to 12 samples, fresh or frozen, in parallel using the carousel adaptor. The adaptor is coolable for sensitive applications such as plant disruption, preventing degradation. The 12 sample format has an additional benefit for current QIAGEN automation users - seamless integration of sample disruption with other QIAGEN automation such as the QIAcube® for purification and QIAxcel® for analysis.
"Our customers continue to require automation to enable them to increase efficiencies in the lab. Earlier this year, we launched three new instruments to assist in that effort, and today we bring one more, the TissueLyser LT," said Dr. Achim Quandt, Senior Global Product Manager, RNA products. "This instrument provides the unique combination of efficient disruption and easy operation in a small instrument. Yet one more way for researchers to integrate automation into all steps of their workflow."
In addition to the newest offerings for RT-PCR analysis, QIAGEN today announces the launch of AllStars Control siRNA for transfection optimization in mouse and rat cells. Allstars Control siRNA enables easy transfection optimization with phenotypic control siRNA in virtually all mouse and rat cell types. Control siRNA is used for transfection optimization and as a positive control in high- throughput screening in mouse and rat cells.
AllStars Control siRNA is just one of the 1.5 million siRNAs and RT-PCR assays that can be ordered through the GeneGlobe® Web portal (www.qiagen.com/GeneGlobe). GeneGlobe allows customers to search for assays for the entire human, mouse, and rat genomes. With some recent updates, researchers can now search not only by gene, but also by pathway; there are currently 300 available on the site. Site visitors need only enter the gene name, accession number, pathway, or other keyword at the GeneGlobe search page to find the range of products available for their target gene.
More information about these products, including photos, is available at www.qiagen.com.
QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated biomolecules visible. QIAGEN has developed and markets more than 500 consumable products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the digene HPV Test, which is regarded as the "gold standard" in testing for high-risk types of human papillomavirus (HPV), the primary cause of cervical cancer. QIAGEN employs more than 3,000 people in over 30 locations worldwide. Further information about QIAGEN can be found at http://www.qiagen.com/.